Send to

Choose Destination
J Laryngol Otol. 2009 Jan;123(1):54-60. doi: 10.1017/S0022215108003770. Epub 2008 Oct 17.

Randomised, double-blinded, placebo-controlled, clinical trial of ozone therapy as treatment of sudden sensorineural hearing loss.

Author information

Department of ORL Head and Neck Surgery, Menofia University Hospital, Egypt.



To investigate the safety and efficacy of ozone therapy in adult patients with sudden sensorineural hearing loss.


Prospective, randomised, double-blinded, placebo-controlled, parallel group, clinical trial.


Forty-five adult patients presented with sudden sensorineural hearing loss, and were randomly allocated to receive either placebo (15 patients) or ozone therapy (auto-haemotherapy; 30 patients). For the latter treatment, 100 ml of the patient's blood was treated immediately with a 1:1 volume, gaseous mixture of oxygen and ozone (from an ozone generator) and re-injected into the patient by intravenous infusion. Treatments were administered twice weekly for 10 sessions. The following data were recorded: pre- and post-treatment mean hearing gains; air and bone pure tone averages; speech reception thresholds; speech discrimination scores; and subjective recovery rates.


Significant recovery was observed in 23 patients (77 per cent) receiving ozone treatment, compared with six (40 per cent) patients receiving placebo (p < 0.05). Mean hearing gains, pure tone averages, speech reception thresholds and subjective recovery rates were significantly better in ozone-treated patients compared with placebo-treated patients (p < 0.05).


Ozone therapy is a significant modality for treatment of sudden sensorineural hearing loss; no complications were observed.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Cambridge University Press
Loading ...
Support Center